Related Experiment Video
Updated: Jun 16, 2026
In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
A new approach for potential drug target discovery through in silico metabolic pathway analysis using Trypanosoma
Marcelo Alves-Ferreira1, Ana Carolina Ramos Guimarães, Priscila Vanessa da Silva Zabala Capriles
1Laboratório de Genômica Funcional e Bioinformática, Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, Brasil.
Abstract:
The current drug options for the treatment of chronic Chagas disease have not been sufficient and high hopes have been placed on the use of genomic data from the human parasite Trypanosoma cruzi to identify new drug targets and develop appropriate treatments for both acute and chronic Chagas disease. However, the lack of a complete assembly of the genomic sequence and the presence of many predicted proteins with unknown or unsure functions has hampered our complete view of the parasite's metabolic pathways. Moreover, pinpointing new drug targets has proven to be more complex than anticipated and has revealed large holes in our understanding of metabolic pathways and their integrated regulation, not only for this parasite, but for many other similar pathogens. Using an in silicocomparative study on pathway annotation and searching for analogous and specific enzymes, we have been able to predict a considerable number of additional enzymatic functions in T. cruzi. Here we focus on the energetic pathways, such as glycolysis, the pentose phosphate shunt, the Krebs cycle and lipid metabolism. We point out many enzymes that are analogous to those of the human host, which could be potential new therapeutic targets.
Insights
Genomic data from Trypanosoma cruzi offers hope for new Chagas disease treatments. Researchers identified potential drug targets by analyzing the parasite's metabolic pathways and enzymes.
Area of Science:
- Parasitology
- Genomics
- Drug Discovery
Background:
- Current treatments for chronic Chagas disease are insufficient.
- Genomic data from Trypanosoma cruzi is crucial for identifying new drug targets.
- Understanding parasite metabolic pathways is key for developing effective therapies.
Purpose of the Study:
- To identify novel drug targets for Chagas disease by analyzing Trypanosoma cruzi's genomic data.
- To improve the understanding of the parasite's metabolic pathways and their regulation.
- To explore potential therapeutic strategies for both acute and chronic Chagas disease.
Main Methods:
- In silico comparative study of pathway annotation.
- Analysis of analogous and specific enzymes in Trypanosoma cruzi.
- Focus on energetic pathways: glycolysis, pentose phosphate shunt, Krebs cycle, and lipid metabolism.
Main Results:
- Predicted numerous additional enzymatic functions in Trypanosoma cruzi.
- Identified several enzymes analogous to human host enzymes.
- Highlighted potential new therapeutic targets within the parasite's metabolic pathways.
Conclusions:
- Genomic analysis of Trypanosoma cruzi reveals potential drug targets for Chagas disease.
- Enzymes analogous to host enzymes represent promising targets for therapeutic intervention.
- Further research into parasite metabolism can lead to improved treatments for Chagas disease.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
01:26Drug Discovery: Overview